Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump's financial disclosures released earlier this year. The Insider SaleEVP of Global Corporate Affairs Vanessa Broadhurst sold 23,054 shares on July 20, a transaction worth close to $5.8 million. Management guides to 6% operational sales growth for 2026, with the company targeting double-digit revenue growth by the end of the decade. Stelara, J&J's older immunology blockbuster, fell YoY as biosimilar competition eats into sales, even though it still posted a 12.8% sequential bump. Rybrevant and Lazcluze, J&J's lung cancer combination, are growing far slower than the $5 billion-plus in 2030 peak sales J&J once projected for them.